Menu
Recruiting NCT06511245

European, Multi-center, Exploratory Trial to Assess WEB Versus Other Endovascular Treatment in Ruptured Aneurysms.

No phase Interventional Ruptured Aneurysm

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Randomisation.
Who it may be relevant to
Registry conditions: Ruptured Aneurysm. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

WEB™ Embolization System in the Treatment of Acutely Ruptured Intracranial Aneurysms Versus Other Endovascular Techniques

Overview

Comparison of efficacy and safety between WEB and other endovascular techniques

Interventions

  • Other Randomisation
    Technique assigned through randomization

Primary outcome measures

  • As exploratory design, one of the outcome will be the assessment of aneurysm occlusion at 12 months using Raymond-Roy scale. [Time frame: 12 months (-3/+6 months)]

Eligibility criteria

Main Inclusion Criteria:

  • Patient is above 18 years of age at the time of consent
  • Patient has an identified acutely ruptured intracranial aneurysm requiring endovascular treatment (for the purposes of this study an acutely ruptured IA patient is defined as a patient with computed tomography (CT), magnetic resonance imaging (MRI), or lumbar puncture (LP) evidence of subarachnoid hemorrhage attributed to the index aneurysm within the last 30 days)
  • Aneurysm dome diameter must be ≤ 10mm and within the diameter (and parent vessel diameter, as appropriate) range treatable by commercially available WEB devices as well as at least one other alternative commercially available endovascular treatment device used per hospital standard practice
  • Aneurysm is located on the anterior communicating artery complex segment (ACom), internal carotid artery terminus (ICAt), anterior cerebral artery (ACA), middle cerebral artery (MCA), basilar apex, posterior communicating artery (PCom) or pericallosal artery
  • Patient must be neurologically stable with a Hunt \& Hess score of I to III
  • Patient or patient's legally authorized representative (LAR) has provided written informed consent

Main Exclusion Criteria:

  • Aneurysm to be treated is unsuitable for endovascular treatment with commercially available WEB devices and/or all other available endovascular treatment techniques used per standard site practice
  • Patient presenting as target aneurysm a blister like or dissecting aneurysm
  • Patient has more than one aneurysm requiring treatment within 30 days of completion of treatment of the target aneurysm
  • Patient with multiple aneurysms in whom ruptured aneurysm cannot be identified
  • Patient has pre-morbid mRS > 2

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

France · 1 center
  • CHU Reims — Reims

Identifiers

NCT: NCT06511245 · CIP EMEA 23-01 · CIP EMEA 23-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗